NOV Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? NOV Inc. Common Stock trades at $18.75 (market cap $6.76B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: NOV Inc. Common Stock is far larger — about 3.8× Vir Biotechnology Inc. Common Stock's market cap, and NOV Inc. Common Stock pays a 1.9% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NOV Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| NOV | VIR | |
|---|---|---|
Market Cap | $6.76B | $1.80B |
Volume | 2,412,554 | 1,782,836 |
Sector | Energy | Health |
52-Week High | $21.71 | $11.78 |
52-Week Low | $12.66 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $7.92B | $1.36B |
Dividend Yield | 1.9% | — |
Signals from Pluang's Aura AI — not financial advice
NOV trades at $18.96, up 0.37% with a bearish technical signal from moving averages. The company reported mixed Q2 2026 results, beating EPS estimates but showing revenue decline. Valuation metrics show a high P/E ratio of 70.22 but attractive P/S of 0.81, while profitability remains weak with 1.1% net margin. Recent news highlights strong subsea demand but Middle East risks and weak equipment sales.
The outlook is cautious with analyst consensus at $21.80 target (15% upside) but technical weakness. Investment opportunity lies in energy equipment strength and margin improvements, while risks include geopolitical exposure, competitive pressures, and inconsistent earnings performance. The stock faces headwinds from capital spending constraints in the oilfield sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NOV provides technology, equipment, and services for energy production. Its offerings support drilling, well construction, and production across oil, gas, renewables, and emerging energy markets.
Read more on NOV →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →